Treatment discontinuation patterns of anti-VEGF in retinal vein occlusion.

Objective: The purpose of this research is to report on real-world anti-vascular endothelial growth factor (anti-VEGF) treatment patterns in retinal vein occlusions (RVO).

Design: Retrospective cohort study.

Participants: Treatment-naive RVO patients initiating anti-VEGF injections between 2015 and 2021.

Patterns of anti-vascular endothelial growth factor discontinuation in neovascular age-related macular degeneration.

Objective: To report on anti-vascular endothelial growth factor (anti-VEGF) discontinuation in neovascular age-related macular degeneration (nAMD).

Design: Retrospective cohort study.

Participants: Treatment-naive nAMD patients initiating anti-VEGF injections between 2015 and 2021.

The effectiveness of ocriplasmin versus surgery for the treatment of macular holes: A systematic review and meta-analysis.

Objective: To conduct a systematic review looking at the effects of ocriplasmin compared to pars plana vitrectomy on macular holes to assess the effectiveness of the treatment options.

Methods: Literature was searched through MEDLINE, EMBASE, CINAHL, Clinical Trials.gov, and ProQuest Dissertations and Theses until June 12, 2018.

Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture.

Purpose: To analyze the safety of different concentrations of anti-VEGF on retinal cells.

Methods: Non-diabetic and streptozotocin (STZ)-induced diabetic rats received intravitreal rat anti-VEGF injections that had final vitreous concentrations of 0, 0.0625, 0.

Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients.

To evaluate long-term structural and functional changes that happen to the optic nerve and retina following ranibizumab (Lucentis) injections in diabetic macular edema (DME) patients. Patients with clinically significant DME requiring anti-VEGF injections underwent pre-injection baseline, 6, 12, and 24 month follow-up tests. The tests performed were optical coherence tomography (OCT), best-corrected visual acuity (BCVA), and visual field (VF).

Combination therapy in exudative age-related macular degeneration: visual outcomes following combined treatment with photodynamic therapy and intravitreal bevacizumab.

Objective: To measure visual outcomes following combined treatment with photodynamic therapy (PDT) and intravitreal bevacizumab for exudative age-related macular degeneration (AMD).

Design: Single-centre, retrospective cohort analysis.

Participants: One hundred and seventy-four eyes in 174 patients, representing a consecutive series of all patients with at least 6 months' follow-up after combined treatment with PDT and bevacizumab for exudative AMD.

Age-related macular degeneration and low-vision rehabilitation: a systematic review.

Background: Because of the prevalence and devastating consequences of age-related macular degeneration (AMD), a systematic review devoted to low-vision rehabilitation and AMD seems timely and appropriate.

Methods: Several electronic databases were searched for studies from 1980 to 2006 involving individuals with low vision or visual impairment and rehabilitation interventions. Studies were assessed for quality and level of evidence.

Prospective evaluation of digital non-stereo color fundus photography as a screening tool in age-related macular degeneration.

Purpose: To evaluate mydriatic, non-stereo digital color fundus photographs as a screening tool for identifying and classifying exudative age-related macular degeneration (AMD).

Design: Prospective case series.

Methods: Digital color fundus photographs were obtained from patients seen in the AMD screening clinic over a 9-month period at the Ivey Eye Institute in London, Ontario.